MGLL and Parkinson disease: Aymerich et al. have shown that the monoacylglycerol lipase (MAGL) inhibitor JZL184 exerted neuroprotective effects in an in vitro cellular PD model that consists of SH-SY5Y cells treated with 1-methyl-4-phenylpyridinium iodide (MPP+) [50].